⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRXP News
NRX Pharmaceuticals, Inc. Common Stock
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
globenewswire.com
NRXP
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
globenewswire.com
NRXP
Form 8-K
sec.gov
NRXP
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
globenewswire.com
NRXP
Form 8-K
sec.gov
NRXP
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
globenewswire.com
NRXP
Form 8-K
sec.gov
NRXP
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
globenewswire.com
NRXP
Form 8-K
sec.gov
NRXP
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
globenewswire.com
NRXP